Does specific inhibition of the nuclear exporter exportin-1 attenuate kidney cancer growth?
The orally-available XPO1 inhibitor, KPT-330, represents a novel target for RCC whose in vivo efficacy approaches that of sunitinib. In addition, cells resistant to KPT-330 retain their ability to respond to available RCC therapeutics suggesting a novel approach for treatment in KPT-330-naïve as well as -resistant RCC patients.
Number of SLNs removed varies based on risk factors for SLN metastasis or false-negative SLN biopsy.